BEARINGPOINT
17.9.2020 08:57:22 CEST | Business Wire | Press release
Management and technology consultancy BearingPoint announced today that it has acquired Paris-based Steerio, an engagement platform (SaaS) that leverages smart analytics to push teamwork, feedback and decision-making into the digital age. With the acquisition, BearingPoint expands its portfolio of team and project management assets and enhances its People & Strategy offering that focuses on the people dimension of a company’s strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005793/en/
The acquisition is part of a bigger strategic move: the independent consulting firm has been investing for years in new and better ways of working. This includes innovative project and team management and collaboration solutions across business units, countries and teams for more innovation, agile-working, and remote and mobile working - an approach embedded in the firm’s Strategy 2025, which puts people in the center. To accelerate this ambition, BearingPoint also created and included data-driven digital assets and managed services in its portfolio.
Steerio joins BearingPoint’s portfolio of team and project management assets such as Active Manager and enhances its People & Strategy offering. BearingPoint said Steerio will be rolled out to all projects of a certain size and complexity and will form a substantial pillar of the way the firm delivers consulting projects.
“The new normal demands that we create and bring to life new ways of working and related offerings,” said Kiumars Hamidian, Managing Partner BearingPoint. “Putting people in the center is a major ambition driving our Strategy 2025, and the acquisition of Steerio fits well with our portfolio of offerings because Steerio is both people-centric and data-driven at the same time. The Steerio platform opens even more innovative ways to collaborate across teams and firms for the best possible outcomes for our clients.”
“Working and collaboration in the 'new normal' is more important than ever, and Steerio’s smart analytics create an augmented project experience for all our team members, which we especially need in these times of remote working,” adds Damien Palacci, Global Leader Consulting Portfolio at BearingPoint. “It is another tool for us to use and leverage for better teamwork, knowledge transfer, and more innovation. And it also empowers employees and helps them take ownership and be entrepreneurs.”
Steerio captures weak signals and uses “soft-data” analytics and best-practices and team feedback to identify roadblocks and adopt best-practices proactively to secure team effectiveness. It reduces project failure and delays and promotes transparency and trust. Every stakeholder has access to anonymized and objective team results.
“Becoming part of BearingPoint is a giant leap for us, as it significantly increases our ability to provide a wider array of services to our clients,” said Damien Guery, Co-Founder of Steerio. “We can now combine our expertise and assets and leverage them with BearingPoint's extensive industry network. We are going to be able to push teamwork and decision-making into the digital age.”
About Steerio
Paris-based Steerio was started to bring teamwork, feedback and decision-making to the digital age, combining years of practical experience, best-practice methodologies and knowledge in artificial intelligence. By leveraging new types of data and enabling decision makers to access the relevant insights at the right time, Steerio unlocks tremendous efficiency gains in team delivery and improves the collaboration experience while reducing the gap between strategy design and execution.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint's clients include many of the world's leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005793/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
